Nitric oxide, a double edged sword in cancer biology: searching for therapeutic opportunities

Simone Mocellin1, Vincenzo Bronte, Donato Nitti

  • 1Department of Oncological and Surgical Sciences, School of Medicine, University of Padova, Padova, Italy. mocellins@hotmail.com

Medicinal Research Reviews
|September 23, 2006
PubMed

Insights

Nitric oxide (NO) impacts cancer through complex mechanisms, yielding conflicting results. NO is a signal transducer, not a universal target, requiring tailored cancer therapies.

Area of Science:

  • Oncology
  • Molecular Biology
  • Biochemistry

Background:

  • Nitric oxide (NO) is a key molecule in physiological and pathological processes.
  • Recent advances highlight NO's complex role in cancer development and progression.
  • Conflicting findings exist regarding NO's net impact on tumor behavior.

Purpose of the Study:

  • To clarify the dual role of nitric oxide in cancer pathogenesis.
  • To define the therapeutic potential of nitric oxide-centered anticancer strategies.
  • To understand the complex interactions between NO levels and tumor development.

Main Methods:

  • Review of existing literature on nitric oxide biology in cancer.
  • Analysis of preclinical data on anti-NO and NO-based anticancer strategies.
  • Integration of molecular and cellular events affected by NO in tumor biology.

Main Results:

  • Nitric oxide exhibits both pro- and anti-tumorigenic effects.
  • Both NO-lowering and NO-releasing strategies show efficacy in preclinical cancer models.
  • The precise impact of NO depends on context and concentration.

Conclusions:

  • Nitric oxide is a complex signal transducer in cancer, not a simple target.
  • Therapeutic strategies targeting NO must be individualized based on cancer's molecular profile.
  • Modulating NO metabolism requires a dynamic understanding of tumor biology and drug interactions.

Related Concept Videos

Nitric Oxide Signaling Pathway01:28

Nitric Oxide Signaling Pathway

Nitric oxide (NO), an inorganic gas, acts as a potent second messenger in most animal and plant tissues. NO diffuses out of the cells that produce it and enters the neighboring cells to generate a downstream response. NO synthase (NOS) catalyzes NO production by the deamination of the amino acid arginine. There are three isoforms of NOS. Endothelial cells have endothelial NOS (eNOS), nerve and muscle cells have neuronal NOS (nNOS), and macrophages produce inducible NOS (iNOS) upon exposure to...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Regulation of Angiogenesis and Blood Supply01:24

Regulation of Angiogenesis and Blood Supply

Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits.  Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl hydroxylase and factor...
Mechanism of Angiogenesis01:10

Mechanism of Angiogenesis

Blood vessel formation starts early during embryonic development, around day 7. In the extraembryonic yolk sac, mesodermal precursor cells called hemangioblast proliferate and differentiate into angioblast. Angioblasts express vascular endothelial growth factor receptor 2 or VEGFR2, which binds VEGF-A, a proangiogenic factor, guiding blood vessel formation. VEGF signaling promotes angioblasts to form a blood island in the developing embryo. Angioblasts further differentiate, giving rise to...